Loading
TRK-950 is an experimental investigational agent whose form is not stated in the registry from Toray Industries in phase 2 trials for gastric & gastro-oesophageal junction cancer and melanoma, aimed at NTRK.
TRK-950 is an investigational agent whose form is not stated in the registry developed by Toray Industries. Its target is NTRK. ClinicalTrials.gov describes the intervention as: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in gastric & gastro-oesophageal junction cancer and melanoma. The largest, NCT06038578, plans to enrol 146 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Investigational agent whose form is not stated in the registry directed at NTRK, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to NTRK.
1.TRK-950 binds NTRK.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TRK-950" OR ABSTRACT:"TRK-950") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TRK-950, not a curated reading list.
Shares Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
Shares NTRK and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.